Pre-BCR and STAT5 Signaling in Acute Lymphoblastic Leukemia
Pre-BCR and STAT5 Signaling in Acute Lymphoblastic Leukemia
批准号:
10059179
负责人:
Michael Archibald Farrar
金额:
$37.67万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-01-01 至 2023-12-31
关键词:
Acute Lymphocytic LeukemiaAdultAllelesB Cell ProliferationB cell differentiationB-Cell Acute Lymphoblastic LeukemiaB-Cell DevelopmentB-LymphocytesBindingCREBBP geneCancer RelapseCause of DeathCell CycleCessation of lifeChIP-seqChildChildhoodChromatinComplexDataDefectDevelopmentDisease OutcomeEP300 geneEnhancersEnsureEpigenetic ProcessEquilibriumFeedbackGene DosageGenesGenetic TranscriptionGrantHDAC3 geneHealthHistone DeacetylaseHumanIRF4 geneLeadLoxP-flanked alleleMalignant Childhood NeoplasmMalignant NeoplasmsMolecularMusNCOR1 geneOncogenesPAX5 genePathway interactionsPatientsPlayProcessPrognosisRoleSMARCA4 geneSamplingSignal TransductionSiteStat5 proteinTestingTumor Suppressor GenesTumor Suppressor Proteinscell transformationchromatin remodelingcohortgenetic corepressorgenome-widehistone acetyltransferaseleukemiamouse modelpreventprogenitorrecruittranscription factortranscriptome sequencing
中文摘要
项目摘要
祖细胞B细胞急性淋巴细胞白血病(B-ALL)是儿童中最常见的癌症形式。
虽然在治疗患有这种癌症的儿童方面取得了实质性进展,但复发性B-ALL仍然是一种严重的疾病。
是儿童癌症死亡人数最多的地区。B-ALL在成人中不太常见,但他们的
预后差得多(~40%存活)。因此,B-ALL仍然是一个重大的健康挑战。实质性
现在有证据表明JAK/STAT 5通路的激活与B-ALL的发展有关。
同样地,编码B细胞所需的转录因子网络的基因中的单等位基因缺失也是可能的。
包括IKZF 1、PAX 5和EBF 1在内的多种细胞因子在人类B-ALL中经常观察到。我们之前
建立了STAT 5激活与前BCR途径中的缺陷合作,最终影响了
包括PAX 5、EBF 1、PU. 1、IRF 4和IKZF 1(下文统称)的转录因子网络
作为PEPII因子)以启动转化。因此,我们的研究结果表明,保持适当的
STAT 5活化和PEPII因子之间的平衡对于引导正常B细胞分化是重要的
和阻止B细胞转化。一个关键的问题仍然是这两个相反的转录
网络的功能是控制B细胞的发育和白血病的发生。我们的初步研究表明,
STAT 5和PEPII与超级增强子内的附近位点结合,并招募相反的表观遗传修饰剂,如
如组蛋白乙酰转移酶(HAT)和脱乙酰酶(HDAC)。额外的初步ChIP-Seq数据显示,
STAT 5和染色质重塑剂BRG 1在多个增强子处的共定位。我们建议
通过STAT 5和PEPII因子募集特异性HAT、HDACS和染色质重塑
以促进正常B细胞发育的方式依次改变增强子景观。
因此,我们的基本假设是STAT 5和PEPII转录网络参与了
仔细协调的反馈回路,以确保适当的祖B细胞扩增,
随后退出细胞周期,分化为小的前B细胞阶段。我们进一步建议
这个网络中的扰动会导致转变。这些假设将在
以下两个具体目标:(1)建立STAT 5改变增强子景观的机制
在B细胞发育和转化过程中,以及(2)确定STAT 5和PEPII因子如何调节
在B细胞分化和转化过程中的癌基因。这些目标的成功实现,
两个相反的转录网络如何控制正常的B细胞发育,
该网络允许最初的祖B细胞转化以及随后的逆转,
转化过程
英文摘要
Project Summary
Progenitor B cell acute lymphoblastic leukemia (B-ALL) is the most common form of cancer in children.
Although substantial progress has been made in treating children with this form of cancer, relapsed B-ALL still
accounts for the highest number of childhood deaths due to cancer. B-ALL is less common in adults but their
prognosis is much poorer (~40% survival). Thus, B-ALL remains a significant health challenge. Substantial
evidence now exists that activation of the JAK/STAT5 pathway is associated with the development of B-ALL.
Likewise, mono-allelic deletions in genes encoding a network of transcription factors required for B cell
development, including IKZF1, PAX5 and EBF1, are frequently observed in human B-ALL. We previously
established that STAT5 activation cooperates with defects in a pre-BCR pathway that ultimately impinges on a
network of transcription factors including PAX5, EBF1, PU.1, IRF4 and IKZF1 (referred to collectively hereafter
as PEPII factors) to initiate transformation. Thus, our findings demonstrated that maintaining appropriate
balance between STAT5 activation and PEPII factors is important for entraining normal B cell differentiation
and preventing B cell transformation. A key question that remains is how these two opposing transcriptional
networks function to govern B cell development and leukemia initiation. Our preliminary studies suggest that
STAT5 and PEPII bind to nearby sites within super-enhancers and recruit opposing epigenetic modifiers, such
as histone acetyltransferases (HATs) and deacetylases (HDACs). Additional preliminary ChIP-Seq data show
co-localization between STAT5 and the chromatin remodeler BRG1 at multiple enhancers. We propose that
recruitment of specific HATs, HDACS and chromatin remodelers by STAT5 and PEPII factors
sequentially alters the enhancer landscape in a manner that promotes normal B cell development.
Thus, our underlying hypothesis is that STAT5 and the PEPII transcriptional network are involved in
carefully orchestrated feedback loops to ensure both appropriate progenitor B cell expansion, and
subsequent exit from cell cycle with differentiation to the small pre-B cell stage. We further propose
that perturbations in this network lead to transformation. These hypotheses will be explored in the
following two specific aims: (1) Establish the mechanism by which STAT5 alters the enhancer landscape
during B cell development and transformation, and (2) Establish how STAT5 and PEPII factors regulate
oncogenes during B cell differentiation and transformation. Successful completion of these aims will illuminate
how two opposing transcriptional networks function to govern normal B cell development and how perturbing
that network allows for both initial progenitor B cell transformation as well as subsequent reversal of the
transformation process.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulatory T Cells in Alzheimer's Disease
-
批准号:10515396
-
项目类别:
-
资助金额:$76.88万
-
财政年份:2022
-
负责人:Michael Archibald Farrar
-
依托单位:
Regulation of central tolerance and Treg development by recirculating Treg
-
批准号:10615598
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2022
-
负责人:Michael Archibald Farrar
-
依托单位:
Regulation of central tolerance and Treg development by recirculating Treg
-
批准号:10363236
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2022
-
负责人:Michael Archibald Farrar
-
依托单位:
Regulatory T Cells in Alzheimer's Disease
-
批准号:10685434
-
项目类别:
-
资助金额:$76.88万
-
财政年份:2022
-
负责人:Michael Archibald Farrar
-
依托单位:
Co-repressors in STAT5-dependent CD4+ T Cell Development and Function
-
批准号:10614429
-
项目类别:
-
资助金额:$48.48万
-
财政年份:2019
-
负责人:Michael Archibald Farrar
-
依托单位:
Pre-BCR and STAT5 Signaling in Acute Lymphoblastic Leukemia
-
批准号:10319979
-
项目类别:
-
资助金额:$36.91万
-
财政年份:2019
-
负责人:Michael Archibald Farrar
-
依托单位:
Pre-BCR and STAT5 Signaling in Acute Lymphoblastic Leukemia
-
批准号:10550155
-
项目类别:
-
资助金额:$36.91万
-
财政年份:2019
-
负责人:Michael Archibald Farrar
-
依托单位:
Co-repressors in STAT5-dependent CD4+ T Cell Development and Function
-
批准号:10382260
-
项目类别:
-
资助金额:$48.48万
-
财政年份:2019
-
负责人:Michael Archibald Farrar
-
依托单位:
Development of Immune Tolerance
-
批准号:10338131
-
项目类别:
-
资助金额:$46.01万
-
财政年份:2016
-
负责人:Michael Archibald Farrar
-
依托单位:
Development of Immune Tolerance
-
批准号:10573296
-
项目类别:
-
资助金额:$45.37万
-
财政年份:2016
-
负责人:Michael Archibald Farrar
-
依托单位:
TNF Receptor Superfamily Signaling in Immune Tolerance
-
批准号:8894185
-
项目类别:
-
资助金额:$37.64万
-
财政年份:2014
-
负责人:Michael Archibald Farrar
-
依托单位:
(PQB3) CD4 T cell response to BCR-ABL-positive Leukemia
-
批准号:9063487
-
项目类别:
-
资助金额:$31.23万
-
财政年份:2014
-
负责人:Michael Archibald Farrar
-
依托单位:
(PQB3) CD4 T cell response to BCR-ABL-positive Leukemia
-
批准号:9262063
-
项目类别:
-
资助金额:$31.23万
-
财政年份:2014
-
负责人:Michael Archibald Farrar
-
依托单位:
(PQB3) CD4 T cell response to BCR-ABL-positive Leukemia
-
批准号:8686567
-
项目类别:
-
资助金额:$31.03万
-
财政年份:2014
-
负责人:Michael Archibald Farrar
-
依托单位:
Pre-BCR and STAT5 Signaling in Acute Lymphoblastic Leukemia
-
批准号:8230503
-
项目类别:
-
资助金额:$31.06万
-
财政年份:2011
-
负责人:Michael Archibald Farrar
-
依托单位:
Transponson-based screens for genes involved in acute lymphoblastic Leukemia
-
批准号:8307275
-
项目类别:
-
资助金额:$30.72万
-
财政年份:2011
-
负责人:Michael Archibald Farrar
-
依托单位:
Pre-BCR and STAT5 Signaling in Acute Lymphoblastic Leukemia
-
批准号:8617815
-
项目类别:
-
资助金额:$30.11万
-
财政年份:2011
-
负责人:Michael Archibald Farrar
-
依托单位:
Transponson-based screens for genes involved in acute lymphoblastic Leukemia
-
批准号:8843379
-
项目类别:
-
资助金额:$28.95万
-
财政年份:2011
-
负责人:Michael Archibald Farrar
-
依托单位:
Pre-BCR and STAT5 Signaling in Acute Lymphoblastic Leukemia
-
批准号:8105994
-
项目类别:
-
资助金额:$31.0万
-
财政年份:2011
-
负责人:Michael Archibald Farrar
-
依托单位:
Transponson-based screens for genes involved in acute lymphoblastic Leukemia
-
批准号:8677789
-
项目类别:
-
资助金额:$28.64万
-
财政年份:2011
-
负责人:Michael Archibald Farrar
-
依托单位:
海外基金